ESMO-ASCO joint symposium: the evolution of the clinical trials landscape

ADAPTING ORGANISATION AND RESEARCH INFRASTRUCTURES AT GUSTAVE ROUSSY FOR TODAY'S CLINICAL RESEARCH PROGRAMMES

A.M.M. Eggermont
Institut Gustave Roussy, Villejuif, FRANCE

Integration of basic-transitional-clinical research to create an interactive continuum, within one infrastructural approach, has been the focus over the recent years at the Gustave Roussy Comprehensive Cancer Center. This continuum of cancer research activities is to articulate with cancer care and to advance with a key mission of the institute: to create tomorrow's medicine. In order to achieve this a number of basic decisions had to be taken: 1) Adapt your clinical research infrastructures to the importance of creating a critical mass activity in early drug development. This was achieved by the creation of a department of drug development and treatment innovations harbouring all early clinical trial activities including the organizational and monitoring aspects. 2) Develop and advance personalized cancer medicine by conducting clinical trials in this domain. This requested the creation of a molecular portrait platform that can deliver within in context of clinical requirements in terms of quality and speed. For this a whole floor of a 6000 M2 new translational research building was reserved and equipped, including bioinformatics. 3) Develop adequate infrastructural support in persons and platforms to participate in the revolution in immunotherapy of cancer. For this dedicated immunotherapists were recruited and an immunotherapy-monitoring platform was created. 4) Develop hi-tech platforms to accommodate on the one hand clinical trial requirements in personalized cancer medicine as indicated under points 1-2-3, as well as basic research platforms that a mutualized by all groups 5) Develop a model where a CCC will evolve into a Cancer Campus by creating and/or expanding large scale preclinical research facilities that will be a prerequisite to attract research branches of pharma, biotech, hi-tech and other private companies to install themselves onto a cancer-center-surrounding biopark: cancer campus 6) Find the money All the above will provide the environment that will attract the best researchers and clinicians and research-clinicians to meet the expectations of society regarding advances to be made in cancer care, which is and remains the endgoal of all we do.

Disclosure: The author has declared no conflicts of interest.